Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20-05-2020
Ugis Rigba / Shutterstock.com
A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Innovative Medicines Initiative, IMI, NGO, PPP, EFPIA, Big Pharma, R&D, IP, licensing, European Commission, biopharmaceuticals
